Sichuan Huiyu Pharmaceutical Co Ltd Total Assets
Sichuan Huiyu Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Sichuan Huiyu Pharmaceutical Co Ltd (688553) holds total assets worth CN¥4.88 Billion CNY (≈ $713.55 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Sichuan Huiyu Pharmaceutical Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
Total assets of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024. This chart illustrates how Sichuan Huiyu Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Sichuan Huiyu Pharmaceutical Co Ltd stock price for real-time trading data and today's change.
Sichuan Huiyu Pharmaceutical Co Ltd - Asset Composition Analysis
Sichuan Huiyu Pharmaceutical Co Ltd Total Assets Breakdown (December 2024)
Sichuan Huiyu Pharmaceutical Co Ltd total assets breakdown as of December 2024. Sichuan Huiyu Pharmaceutical Co Ltd's total assets of CN¥4.88 Billion consist of 64.7% current assets and 35.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 45.1% |
| Accounts Receivable | CN¥58.08 Million | 1.1% |
| Inventory | CN¥159.92 Million | 3.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥86.27 Million | 1.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Sichuan Huiyu Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sichuan Huiyu Pharmaceutical Co Ltd short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sichuan Huiyu Pharmaceutical Co Ltd's current assets represent 64.7% of total assets in 2024, an increase from 17.4% in 2017.
- Cash Position: Cash and equivalents constituted 45.1% of total assets in 2024, up from 2.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 9.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 3.1% of total assets.
Sichuan Huiyu Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Sichuan Huiyu Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
China | CN¥7.35 Billion |
Sichuan Huiyu Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.85 | 2.71 | 1.92 |
| Quick Ratio | 2.63 | 2.57 | 1.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.00 Billion | CN¥1.93 Billion | CN¥363.64 Million |
Sichuan Huiyu Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sichuan Huiyu Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 10.2% |
| Total Assets | CN¥5.17 Billion |
| Market Capitalization | $708.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sichuan Huiyu Pharmaceutical Co Ltd's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sichuan Huiyu Pharmaceutical Co Ltd's assets grew by 10.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total assets of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.17 Billion ≈ $755.89 Million |
+10.24% |
| 2023-12-31 | CN¥4.69 Billion ≈ $685.66 Million |
+9.57% |
| 2022-12-31 | CN¥4.28 Billion ≈ $625.79 Million |
+3.56% |
| 2021-12-31 | CN¥4.13 Billion ≈ $604.28 Million |
+240.51% |
| 2020-12-31 | CN¥1.21 Billion ≈ $177.46 Million |
+41.02% |
| 2019-12-31 | CN¥859.98 Million ≈ $125.84 Million |
+153.45% |
| 2018-12-31 | CN¥339.31 Million ≈ $49.65 Million |
+43.41% |
| 2017-12-31 | CN¥236.61 Million ≈ $34.62 Million |
-- |
About Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more